☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - February 2021

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of February 2021. This month is one technology appraisal that impacts upon primary care.

The Dapagliflozin for treating chronic heart failure with reduced ejection fraction technology appraisal has been published. This treatment is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:

  • angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor blockers (ARBs), with beta blockers and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or
  • sacubitril valsartan, with beta blockers and, if tolerated, MRAs

It is also noted that this treatment should only be started on the advice of a heart failure specialist.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - February 2021' by emailShare 'NICE Guidance - February 2021' on FacebookShare 'NICE Guidance - February 2021' on TwitterShare 'NICE Guidance - February 2021' on LinkedInShare 'NICE Guidance - February 2021' on reddit


No Comments to “NICE Guidance - February 2021”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.